Keratitis
Drug research and approvals for keratitis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 22 studies of keratitis are recruiting on ClinicalTrials.gov, Health Canada has authorized 2 drug trials for it since 2013, FDA has 5 approved and 16 open orphan designations naming it, and the EU has 3 authorised medicines for it.
- Recruiting worldwide: 22
- Trials authorized in Canada: 2
- FDA orphan approvals: 5
- EU medicines: 3
- A Phase 1/2 Clinical Trial to Evaluate the Safety and Efficacy of MR-146 in Subjects With Stage I and Stage II…NCT07923045 · Phase 1 / Phase 2 · Viatris Inc. · starts Nov 1, 2026
- A Multicenter, Randomized, Vehicle-Controlled, Double-Masked to Open-Label Study to Evaluate the Safety and Efficacy of…NCT07568730 · Phase 2 · TearSolutions, Inc. · starts Feb 19, 2026
- Real-World Assessment of VEVYE® for Short-Term Symptom and Sign Improvement of Dry Eye Disease in a Neuro-Ophthalmology…NCT07566975 · Not reported · Neuro-Ophthalmology of Texas · starts Mar 31, 2026
- An Efficacy and Safety Study of Cenegermin Ophthalmic Solution Compared With Vehicle in the Treatment of PCEDNCT07519902 · Phase 3 · Dompé Farmaceutici S.p.A · starts Jun 2, 2026
- Intrastromal Moxifloxacin as an Adjunctive Therapy in Recalcitrant Bacterial KeratitisNCT07394257 · Not applicable · Minia University · starts Oct 1, 2025
- Follow-up Compliance for Corneal Ulcer Patients With SMS ReminderNCT07377513 · Not applicable · Seva Canada Society · starts Feb 23, 2026
- Clinical Study of Intrastromal Anti-VEGF Injection for Corneal Neovascularization.NCT07329686 · Phase 1 / Phase 2 · Second Affiliated Hospital, Zhejiang University, School of Medicine · starts Oct 1, 2025
- A Study Comparing KB801 Verse Placebo in Patients With Stage 2 or 3 Neurotrophic KeratitisNCT06999733 · Phase 1 / Phase 2 · Krystal Biotech, Inc. · starts Jul 7, 2025
- A Phase II Study of STSP-0902 Ophthalmic Solution in Patients With Neurotrophic KeratitisNCT06975748 · Phase 2 · Staidson (Beijing) Biopharmaceuticals Co., Ltd · starts Jun 12, 2025
Approved 6
- CyclosporineCyclophilin A modulator
- GentamicinBacterial 70S ribosome inhibitor
- PrednisoneGlucocorticoid receptor agonist
- Dexamethasone phosphoric acidGlucocorticoid receptor agonist
- DexamethasoneGlucocorticoid receptor agonist
- CenegerminNeurotrophic tyrosine kinase receptor agonist
Phase 3 4
- MoxifloxacinTopoisomerase IV inhibitor
- DifluprednateGlucocorticoid receptor agonist
- Rose bengal free acid
- Ozone
Phase 1 or earlier 2
- Timbetasin
- VoriconazoleCytochrome P450 51 inhibitor
How its trials ended
143 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 33 whose ending is known, 42% met their primary endpoint, 0% missed it and 58% stopped early.
- Completed, result not reported5538%
- Ongoing2920%
- Status unknown2618%
- Met its primary endpoint1410%
- Stopped: other or unclear128%
- Stopped: enrollment or feasibility43%
- Stopped: lack of efficacy32%
| Jul 12, 2022 | A multi-center, randomized, double-masked, vehicle-controlled, parallel-group, study to evaluate the safety and efficacy of CSB-001 ophthalmic solution 0.1% in…CSB-001 | Claris Biotherapeutics | Ongoing |
| Nov 26, 2021 | Topical insulin drops for the treatment of neurotrophic keratopathyHumulin-r | Governors of The University of Alberta | Closed |
| Mar 29, 2019 | AvaclyrAVACLYR is a sterile topical antiviral indicated for the treatment of acute herpetic keratitis (dendritic ulcers) in patients with herpes… | Fera Pharmaceuticals | Approved |
| Aug 22, 2018 | OxervateTreatment of neurotrophic keratitis | Dompe S.p.A. | Approved |
| Sep 15, 2009 | ZirganTreatment of acute herpetic keratitis (dendritic ulcers) | Sirion Therapeutics, Inc. | Approved |
| Feb 18, 2005 | Vaccinia Immune Globulin (Human) IntravenousTreatment and modification of aberrant infections induced by vaccinia virus that include its accidental implantation in eyes (except in… | DynPort Vaccine Company LLC | Approved |
| Sep 23, 1993 | Alomide Ophthalmic SolutionTreatment of ocular disorders referred to by the terms vernal keratoconjunctivitis, vernal conjunctivitis, vernal keratitis. | Alcon Laboratories, Inc. | Approved |
| Jul 14, 2026 | Pathogen-inactivated allogeneic human growth factorTreatment of neurotrophic keratitis | Eye Care International LLC | Designated |
| Jul 14, 2026 | TavilermideTreatment of neurotrophic keratitis (NK) | Mimetogen Pharmaceuticals, Inc. | Designated |
| Mar 17, 2025 | Povidone iodineTreatment of fungal keratitis | IVIEW Therapeutics, Inc | Designated |
| Dec 18, 2024 | LacripepTreatment of neurotrophic keratitis | TearSolutions Inc. | Designated |
| Sep 30, 2024 | Allogeneic human blood serumTreatment of neurotrophic keratitis | Allovision, LLC | Designated |
| Jul 20, 2023 | MeropenemTreatment of bacterial keratitis | Ibiotica, LLC | Designated |
| Jul 5, 2023 | Exosomes purified from primed human bone marrow derived…Treatment of neurotrophic keratitis | Pandorum Technologies, Inc. | Designated |
| Nov 28, 2022 | Pigment Epithelium Derived Factor derived short peptide…Treatment of Neurotrophic Keratitis | BRIM Biotechnology | Designated |
| Jun 24, 2022 | HSV-1-erasing lentivirus-like particle delivering…Treatment of herpes simplex (HSV-1) infected keratitis (HSK) | Hangzhou BDgene Co., Ltd. | Designated |
| Feb 11, 2022 | PolihexanideTreatment of fungal keratitis infection | SIFI SpA | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA